Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 5:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Myoepithelial Carcinoma Clear all

Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

NCT00045669

View directory record Official record

Conditions: Head and Neck Cancer
Interventions: imatinib mesylate; Drug
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years to 120 Years

Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 14
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more

Source: ClinicalTrials.gov public record

Updated Feb 14, 2019 · Synced May 22, 2026, 5:47 AM EDT

Terminated Phase 1 Interventional

A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

NCT05355753

View directory record Official record

Conditions: Synovial Sarcoma, Soft Tissue Sarcoma
Interventions: CFT8634; Drug
Lead sponsor: C4 Therapeutics, Inc.; Industry
Eligibility: 12 Years and older

Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 12
States / cities: Duarte, California • Santa Monica, California • Aurora, Colorado + 8 more

Source: ClinicalTrials.gov public record

Updated Dec 16, 2024 · Synced May 22, 2026, 5:47 AM EDT

Not listed Not applicable Interventional

Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy

NCT01586767

View directory record Official record

Conditions: Adenoid Cystic Carcinoma, Squamous Cell Carcinoma, Sinonasal Carcinoma, Sinonasal Undifferentiated Carcinoma, Mucoepidermoid Carcinoma, Schneiderian Carcinoma, Myoepithelial Carcinoma, Esthesioneuroblastoma, Melanoma
Interventions: Proton radiation therapy, Intensity-modulated radiotherapy; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older

Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Rochester, Minnesota

Source: ClinicalTrials.gov public record

Updated Sep 20, 2023 · Synced May 22, 2026, 5:47 AM EDT

Recruiting Phase 1Phase 2 Interventional

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

NCT06239272

View directory record Official record

Conditions: Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma, Myoepithelioma, Fibrosarcoma NOS, Myxofibrosarcoma, Angiosarcoma, Osteosarcoma, Extraskeletal
Interventions: Surgical resection, Proton beam radiation therapy, Pazopanib, Ifosfamide, Doxorubicin, Selinexor; Procedure · Radiation · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 30 Years

Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 6
States / cities: Chicago, Illinois • Baton Rouge, Louisiana • Boston, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated May 18, 2026 · Synced May 22, 2026, 5:47 AM EDT